Lung cancer
Conditions
Interventions
Experimental group:SBRT
Control group:NA
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 80 years; 2. ECOG 0 – 2 points; 3. Pathologically diagnosed, driver gene detection is sensitive EGFR mutation, initial treatment of stage IV NSCLC (UICC 8th edition), no previous anti-tumor history; 4. No contraindications to molecular targeted therapy and radiotherapy; 5. Appropriate hematological parameters and liver and kidney functions: Absolute neutrophil count >=1.5x10^9/L; platelet count >=75x10^9/L; serum total bilirubin <= 1.5x upper limit of normal; AST and ALT <= 2.5x upper limit of normal (if abnormal liver function is Caused by tumor, AST and ALT <= 5x upper limit of normal); 6. 2-3 months after EGFR-TKIs treatment, the efficacy of the patient is evaluated as PR or SD (refer to 1.1 RECIST 1.1 for the evaluation of efficacy in solid tumors), and the longest diameter of the primary tumor is <=5cm; 7. Sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with disease progression or primary lesions larger than 5 cm after EGFR-TKIs treatment; 2. Active pulmonary tuberculosis; 3. Patients with high bleeding risk: (1) Patients with active peptic ulcer lesions in the stomach and fecal occult blood (++); (2) Those with a history of melena and/or hematemesis within 3 months; 3) Those with abnormal coagulation function and bleeding tendency. 4. Patients with grade 3-4 hypertension; 5. Patients with renal insufficiency stage 3 and above; 6. Patients with hand-foot skin reaction >= grade 3 or above; 7. Uncontrolled concomitant diseases within 6 months before the study, including unstable angina pectoris, acute myocardial infarction, cerebrovascular accident, etc.; 8. Pregnant or breastfeeding patients, or those who are fertile without taking contraceptive measures; 9. History of other malignant tumors, but the disease-free survival period is less than 5 years; 10. Patients taking other anti-tumor therapy or participating in other interventional clinical trials at the same time; 11. Patients who cannot adapt to this study due to psychological, family and social reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression Free Survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactLi Yan
West China Hospital, Sichuan University
Outcome results
None listed